# A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)

> **NCT02110225** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 50 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DRUG:** rhNGF 60 µg/ml eye drops solution
- **DRUG:** rhNGF 180 µg/ml eye drops solution
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02110225
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02110225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02110225, "A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02110225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*